冰岛 - 冰岛文 - LYFJASTOFNUN (Icelandic Medicines Agency)

colgate palmolive a/s - sodium fluoride - tannpasta - 5 mg/g

冰岛 - 冰岛文 - LYFJASTOFNUN (Icelandic Medicines Agency)

medical valley invest ab - hydroxyzinum hýdróklóríð - filmuhúðuð tafla - 25 mg

冰岛 - 冰岛文 - LYFJASTOFNUN (Icelandic Medicines Agency)

mcneil sweden ab - loperamidum hýdróklóríð - filmuhúðuð tafla - 2 mg

冰岛 - 冰岛文 - LYFJASTOFNUN (Icelandic Medicines Agency)

pfizer aps - n.n-dimethyl-4.4-diphenyl-3-butene-2-amine klóríð; cetobemidonum hýdróklóríð - endaþarmsstíll - 10 mg + 50 mg

冰岛 - 冰岛文 - LYFJASTOFNUN (Icelandic Medicines Agency)

viatris aps - magnesii hydroxidum - filmuhúðuð tafla - 500 mg

冰岛 - 冰岛文 - LYFJASTOFNUN (Icelandic Medicines Agency)

orion corporation - bisacodylum inn - sýruþolin tafla og endaþarmsdreifa

冰岛 - 冰岛文 - LYFJASTOFNUN (Icelandic Medicines Agency)

orion corporation - bisacodylum inn - endaþarmsdreifa - 2 mg/ml

冰岛 - 冰岛文 - LYFJASTOFNUN (Icelandic Medicines Agency)

orion corporation - bisacodylum inn - magasýruþolin tafla - 5 mg

欧盟 - 冰岛文 - EMA (European Medicines Agency)

astellas pharma europe b.v. - enzalutamíð - blöðruhálskirtli - innkirtla meðferð - xtandi is indicated for:the treatment of adult men with metastatic hormone-sensitive prostate cancer (mhspc) in combination with androgen deprivation therapy (see section 5. the treatment of adult men with high-risk non-metastatic castration-resistant prostate cancer (crpc) (see section 5. the treatment of adult men with metastatic crpc who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated (see section 5. the treatment of adult men with metastatic crpc whose disease has progressed on or after docetaxel therapy.

冰岛 - 冰岛文 - LYFJASTOFNUN (Icelandic Medicines Agency)

medical valley invest ab - losartanum kalíum - filmuhúðuð tafla - 12,5 mg